Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis

Abstract

Tetraspanins are a conserved family of proteins involved in a number of biological processes. We have previously shown that Tetraspanin-32 (TSPAN32) is significantly downregulated upon activation of T helper cells via anti-CD3/CD28 stimulation. On the other hand, TSPAN32 is marginally modulated in activated Treg cells. A role for TSPAN32 in controlling the development of autoimmune responses is consistent with our observation that encephalitogenic T cells from myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) mice exhibit significantly lower levels of TSPAN32 as compared to naïve T cells. In the present study, by making use of ex vivo and in silico analysis, we aimed to better characterize the pathophysiological and diagnostic/prognostic role of TSPAN32 in T cell immunity and in multiple sclerosis (MS). We first show that TSPAN32 is significantly downregulated in memory T cells as compared to naïve T cells, and that it is further diminished upon ex vivo restimulation. Accordingly, following antigenic stimulation, myelin-specific memory T cells from MS patients showed significantly lower expression of TSPAN32 as compared to memory T cells from healthy donors (HD). The expression levels of TSPAN32 was significantly downregulated in peripheral blood mononuclear cells (PBMCs) from drug-naïve MS patients as compared to HD, irrespective of the disease state. Finally, when comparing patients undergoing early relapses in comparison to patients with longer stable disease, moderate but significantly lower levels of TSPAN32 expression were observed in PBMCs from the former group. Our data suggest a role for TSPAN32 in the immune responses underlying the pathophysiology of MS and represent a proof-of-concept for additional studies aiming at dissecting the eventual contribution of TSPAN32 in other autoimmune diseases and its possible use of TSPAN32 as a diagnostic factor and therapeutic target.

<p>Rituximab Prevents the Development of Experimental Autoimmune Encephalomyelitis (EAE): Comparison with Prophylactic, Therapeutic or Combinational Regimens</p>

“…32 Also, the role of Tetraspanin-32 in MS was explored utilizing ex vivo and in silico analysis. 33 Based on in silico analysis we performed immunohistochemical studies to corroborate the effects of RTX in ameliorating the EAE clinical scores with histological examination of brain tissues. We were intrigued by the effect of high dose, i.e.…”

Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease

“…To this aim, gene expression signatures obtained from -omics data [28] are used to discover novel mechanisms of disease and searches inverse drug-disease relationships by matching gene expression profiles. We and others have used whole-genome expression databases for the better understanding of pathogenic pathways and the prediction of diagnostic and therapeutic strategies for a series of disorders-e.g., immunoinflammatory and autoimmune diseases [29][30][31][32][33][34][35][36][37], and cancer [38,39]-which has led to the identification of potential novel therapeutic targets [40][41][42][43][44][45][46][47][48][49][50][51]. However, gene perturbation alone cannot accurately predict treatment options due to variability related to disease genetics and epigenetics, as well as, experimental settings.…”

Meta-Analysis of Transcriptomic Data of Dorsolateral Prefrontal Cortex and of Peripheral Blood Mononuclear Cells Identifies Altered Pathways in Schizophrenia

“…To our knowledge, this is the first meta-analysis to be performed exclusively on studies performed on a specific brain region from SCZ subjects and controls, rather than on studies encompassing different Brodmann areas or brain anatomical structures. The use of whole-genome expression databases has been largely exploited by our group and others [37][38][39][40][41] for the characterization of pathogenic pathways and to identify therapeutic targets for a variety of disorders, such as autoimmune diseases [42][43][44][45][46][47][48][49][50], cancer [44,51,52], and has allowed researchers to characterize pathogenic pathways [53][54][55][56], and potential therapeutic targets [57][58][59][60][61].…”